Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan

10 Feb 2010

Abstract excerpt

There is no tailored therapy yet for human basal-like mammary carcinomas. However, BRCA1 dysfunction is frequently present in these malignancies, compromising homology-directed DNA repair. This defect may serve as the tumor's Achilles heel and make the tumor hypersensitive to DNA breaks. We have evaluated this putative synthetic lethality in a genetically engineered mouse model for BRCA1-associated breast cancer,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20145144
DOI: 10.1158/0008-5472.can-09-3367

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor TopotecanPMID 20145144Read ↗

EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.Semantic proximity Read ↗

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.Semantic proximity Read ↗

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancerSemantic proximity Read ↗

BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug ResistanceSemantic proximity Read ↗

Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.Semantic proximity Read ↗

The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cellsSemantic proximity Read ↗

Topoisomerase levels determine chemotherapy response <i>in vitro</i> and <i>in vivo</i>Semantic proximity Read ↗

Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast CancerSemantic proximity Read ↗

A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.Semantic proximity Read ↗

Drug resistance in the mouse cancer clinicSemantic proximity Read ↗

Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival.Semantic proximity Read ↗

Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.